Fairvalue-Calculator Fairvalue-Calculator

Boji Medical Technology Co (300404) Fair Value & Analysis

Healthcare · CN · Market cap 3.2B CNY

Price¥8.65
Fair Value¥2.78
Upside-67.9%
Quality92/100
Evidence: High Range ¥2.17 – ¥3.39

Analysis

Boji Medical Technology Co (300404) currently trades at ¥8.65, while our model-based Fair Value estimate is ¥2.78 — implying the stock looks roughly 67.9% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. It offers pre-clinical research, clinical research, and other consulting services. The company also provides clinical drug production, pilot test scale-up, process verification batch production, and drug registration and approval services. In addition, it engages in the screening, evaluation, verification, and trading of technological achievements formed in the process of new drug research and development. The company was formerly known as Guangzhou Boji Medical & Biotechnological Co., Ltd. and changed its name to Boji Medical Technology Co.,Ltd. in September 2021. Boji Medical Technology Co.,Ltd. was founded in 1998 is headquartered in Guangzhou, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Alnylam Pharmaceuticals, Inc (ALNY) -64% Samsung Biologics Co (207940) +9%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.